Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (511-520 of 622) with videos related to

Pageof 63
Sort By:
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
British Journal of Cancer|June 22, 2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialAlison C Backen, Andre Lopes, Harpreet Wasan, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Molecular Cancer Therapeutics|October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid TumorsFranck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
Gut|May 17, 2019
International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesisAlasdair J Scott, James L Alexander, Claire A Merrifield, et al.
Plos Genetics|June 23, 2022
Exome sequencing in multiplex families with left-sided cardiac defects has high yield for disease gene discoveryDavid M Gordon, David Cunningham, Gloria Zender, et al.
The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.
The Lancet. Oncology|July 17, 2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialJuan W Valle, Harpreet Wasan, Andre Lopes, et al.
The New England Journal of Medicine|July 11, 2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerDavid Cunningham, William H Allum, Sally P Stenning, et al.
Clinical Colorectal Cancer|July 26, 2018
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal CancerRaghav Sundar, Susana Miranda, Daniel Nava Rodrigues, et al.
Pageof 63

Showing results (511-520 of 622) with videos related to

Sort By:
Pageof 63
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
British Journal of Cancer|June 22, 2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialAlison C Backen, Andre Lopes, Harpreet Wasan, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Molecular Cancer Therapeutics|October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid TumorsFranck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
Gut|May 17, 2019
International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesisAlasdair J Scott, James L Alexander, Claire A Merrifield, et al.
Plos Genetics|June 23, 2022
Exome sequencing in multiplex families with left-sided cardiac defects has high yield for disease gene discoveryDavid M Gordon, David Cunningham, Gloria Zender, et al.
The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.
The Lancet. Oncology|July 17, 2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialJuan W Valle, Harpreet Wasan, Andre Lopes, et al.
The New England Journal of Medicine|July 11, 2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerDavid Cunningham, William H Allum, Sally P Stenning, et al.
Clinical Colorectal Cancer|July 26, 2018
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal CancerRaghav Sundar, Susana Miranda, Daniel Nava Rodrigues, et al.
Pageof 63